title: Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
abstract: Fluoxetine, citalopram, paroxetine and venlafaxine have been widely used in the treatment of depression. However, no study has been conducted to determine the four drugs simultaneously by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
  
  
  OBJECTIVE
  To establish a new, rapid and sensitive HPLC-MS/ESI method for simultaneous determination and screening in human plasma of the four most commonly prescribed nontricyclic antidepressants: fluoxetine, citalopram, paroxetine and venlafaxine.
  
  
  METHODS
  The analytes in plasma were extracted by solid-phase-extraction column after samples had been alkalinized. The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (250 mmx4.6 mm, 5 microm, Germany) column, using water (formic acid 0.6 per thousand, ammonium acetate: 30 mmol/l)-acetonitrile (35:65, v/v) as mobile phase, with a flow-rate of 0.85 ml/min. The compounds were ionized in the electrospray ionization (ESI) ion source of the mass spectrometer and were detected in the selected ion recording (SIR) mode.
  
  
  RESULTS
  The calibration curves were linear in the 5.0-1000.0 ng/ml range for all compounds, all of them with coefficients of determination above 0.9900. The average extraction recoveries for all the four analytes were above 73.2%. The methodology recoveries were higher than 95.0%. The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively. The intra- and inter-day variation coefficients were less than 15.0%.
  
  
  CONCLUSIONS
  The method is accurate, sensitive and simple for routine therapeutic drug monitoring (TDM) as well as toxicologic screening, and for the study of the pharmacokinetics and metabolism of the four drugs.
authors.affiliation: Clinical Pharmaceutical Research Institute, Second Xiangya Hospital, Central South University, Changsha 410011, PR China. hejuanwin@126.com
authors.forename: He
authors.initials: H
authors.lastname: Juan
authors.forename: Zhou
authors.initials: Z
authors.lastname: Zhiling
authors.forename: Li
authors.initials: L
authors.lastname: Huande
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D015283:Citalopram / Q000097:blood*; D003511:Cyclohexanols / Q000097:blood*; D003863:Depression / Q000188:drug therapy; D005260:Female; D005473:Fluoxetine / Q000097:blood*; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D000069470:Venlafaxine Hydrochloride
chemical_list: D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D005473:Fluoxetine; D015283:Citalopram; D017374:Paroxetine; D000069470:Venlafaxine Hydrochloride